JP2017506264A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017506264A5 JP2017506264A5 JP2016570201A JP2016570201A JP2017506264A5 JP 2017506264 A5 JP2017506264 A5 JP 2017506264A5 JP 2016570201 A JP2016570201 A JP 2016570201A JP 2016570201 A JP2016570201 A JP 2016570201A JP 2017506264 A5 JP2017506264 A5 JP 2017506264A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- combination
- composition according
- ctla
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010028980 Neoplasm Diseases 0.000 claims description 17
- 201000011510 cancer Diseases 0.000 claims description 17
- 230000002401 inhibitory effect Effects 0.000 claims description 8
- 230000037361 pathway Effects 0.000 claims description 8
- 229940045513 CTLA4 antagonist Drugs 0.000 claims description 7
- 206010009944 Colon cancer Diseases 0.000 claims description 6
- 206010006187 Breast cancer Diseases 0.000 claims description 4
- 208000026310 Breast neoplasm Diseases 0.000 claims description 4
- 102000008203 CTLA-4 Antigen Human genes 0.000 claims description 4
- 108010021064 CTLA-4 Antigen Proteins 0.000 claims description 4
- 102100040678 Programmed cell death protein 1 Human genes 0.000 claims description 4
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims description 4
- 239000000556 agonist Substances 0.000 claims description 4
- 208000029742 colonic neoplasm Diseases 0.000 claims description 4
- 239000007787 solid Substances 0.000 claims description 4
- 230000003213 activating effect Effects 0.000 claims description 3
- 208000006468 Adrenal Cortex Neoplasms Diseases 0.000 claims description 2
- 206010004593 Bile duct cancer Diseases 0.000 claims description 2
- 206010005003 Bladder cancer Diseases 0.000 claims description 2
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 2
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 2
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 2
- 208000017604 Hodgkin disease Diseases 0.000 claims description 2
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims description 2
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 2
- 208000005450 Maxillary Sinus Neoplasms Diseases 0.000 claims description 2
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 2
- 206010033128 Ovarian cancer Diseases 0.000 claims description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 2
- 206010038389 Renal cancer Diseases 0.000 claims description 2
- 206010041067 Small cell lung cancer Diseases 0.000 claims description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 2
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 2
- 208000026900 bile duct neoplasm Diseases 0.000 claims description 2
- 201000010881 cervical cancer Diseases 0.000 claims description 2
- 208000006990 cholangiocarcinoma Diseases 0.000 claims description 2
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 claims description 2
- 201000004101 esophageal cancer Diseases 0.000 claims description 2
- 206010017758 gastric cancer Diseases 0.000 claims description 2
- 201000010982 kidney cancer Diseases 0.000 claims description 2
- 201000007270 liver cancer Diseases 0.000 claims description 2
- 208000014018 liver neoplasm Diseases 0.000 claims description 2
- 201000004488 maxillary sinus cancer Diseases 0.000 claims description 2
- 208000019303 maxillary sinus carcinoma Diseases 0.000 claims description 2
- 201000001441 melanoma Diseases 0.000 claims description 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 2
- 208000000587 small cell lung carcinoma Diseases 0.000 claims description 2
- 201000011549 stomach cancer Diseases 0.000 claims description 2
- 201000002510 thyroid cancer Diseases 0.000 claims description 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 2
- 108040006849 interleukin-2 receptor activity proteins Proteins 0.000 claims 2
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN499/DEL/2014 | 2014-02-21 | ||
| IN499DE2014 | 2014-02-21 | ||
| IN3087/DEL/2014 | 2014-10-29 | ||
| IN3087DE2014 | 2014-10-29 | ||
| PCT/IN2015/000099 WO2015125159A1 (en) | 2014-02-21 | 2015-02-20 | Il-2rbeta-selective agonists in combination with an anti-ctla-4 antibody or an an anti-pd-1 antibody |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019016875A Division JP2019077723A (ja) | 2014-02-21 | 2019-02-01 | 抗ＣＴＬＡ−４抗体又は抗ＰＤ−１抗体との併用におけるＩＬ−２Ｒβ選択的作動薬 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017506264A JP2017506264A (ja) | 2017-03-02 |
| JP2017506264A5 true JP2017506264A5 (cg-RX-API-DMAC7.html) | 2018-01-18 |
| JP6963385B2 JP6963385B2 (ja) | 2021-11-10 |
Family
ID=53055076
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016570201A Active JP6963385B2 (ja) | 2014-02-21 | 2015-02-20 | 抗ＣＴＬＡ−４抗体又は抗ＰＤ−１抗体との併用におけるＩＬ−２Ｒβ選択的作動薬 |
| JP2019016875A Withdrawn JP2019077723A (ja) | 2014-02-21 | 2019-02-01 | 抗ＣＴＬＡ−４抗体又は抗ＰＤ−１抗体との併用におけるＩＬ−２Ｒβ選択的作動薬 |
| JP2021018007A Withdrawn JP2021073296A (ja) | 2014-02-21 | 2021-02-08 | 抗ＣＴＬＡ−４抗体又は抗ＰＤ−１抗体との併用におけるＩＬ−２Ｒβ選択的作動薬 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019016875A Withdrawn JP2019077723A (ja) | 2014-02-21 | 2019-02-01 | 抗ＣＴＬＡ−４抗体又は抗ＰＤ−１抗体との併用におけるＩＬ−２Ｒβ選択的作動薬 |
| JP2021018007A Withdrawn JP2021073296A (ja) | 2014-02-21 | 2021-02-08 | 抗ＣＴＬＡ−４抗体又は抗ＰＤ−１抗体との併用におけるＩＬ−２Ｒβ選択的作動薬 |
Country Status (21)
Families Citing this family (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2655409A4 (en) | 2010-12-22 | 2015-07-01 | Univ Leland Stanford Junior | SUPERAGONISTS AND ANTAGONISTS OF INTERLEUKIN-2 |
| WO2017123981A1 (en) | 2016-01-15 | 2017-07-20 | Rfemb Holdings, Llc | Immunologic treatment of cancer |
| EP3077041B1 (en) | 2013-12-05 | 2024-07-10 | Rfemb Holdings LLC | Cancer immunotherapy by radiofrequency electrical membrane breakdown (rf-emb) |
| HUE046249T2 (hu) | 2013-12-12 | 2020-02-28 | Shanghai hengrui pharmaceutical co ltd | PD-1 antitest, antigén-kötõ fragmense, és gyógyászati alkalmazása |
| PL3134123T3 (pl) | 2014-02-21 | 2021-07-12 | Nektar Therapeutics (India) Pvt. Ltd. | Agoniści selektywni względem IL-2Rbeta w kombinacji z przeciwciałem anty-CTLA-4 lub z przeciwciałem anty-PD-1 |
| CN106659757B (zh) | 2014-04-24 | 2022-01-28 | 利兰斯坦福初级大学董事会 | 白介素2的超级激动剂、部分激动剂和拮抗剂 |
| CA2975123A1 (en) | 2015-01-30 | 2016-08-04 | Rfemb Holdings, Llc | Radio frequency electrical membrane breakdown for the treatment of high risk and recurrent prostate cancer, unresectable pancreatic cancer, tumors of the breast, melanoma or other skin malignancies, sarcoma, soft tissue tumors, ductal carcinoma, neoplasia, and intra and extra luminal abnormal tissue |
| BR112018000917A2 (pt) | 2015-07-16 | 2018-09-11 | Bioxcel Therapeutics Inc | abordagem inovadora para o tratamento de câncer através da imunomodulação |
| US11262360B2 (en) | 2015-10-02 | 2022-03-01 | Julius-Maximilians-Universität Würzburg | GDF-15 as a diagnostic marker to predict the clinical outcome of a treatment with immune checkpoint blockers |
| WO2017062832A1 (en) | 2015-10-08 | 2017-04-13 | Nektar Therapeutics | Combination of an il-2rbeta-selective agonist and a long-acting il-15 agonist |
| KR20250065935A (ko) | 2015-11-20 | 2025-05-13 | 센화 바이오사이언시즈 인코포레이티드 | 암을 치료하기 위한 테트라사이클릭 퀴놀론 유사체의 병행 요법 |
| TW201735949A (zh) | 2016-03-24 | 2017-10-16 | 千禧製藥公司 | 治療抗ctla4及抗pd-1組合治療中的胃腸道免疫相關不良事件之方法 |
| JP7069032B2 (ja) | 2016-03-24 | 2022-05-17 | ミレニアム ファーマシューティカルズ， インコーポレイテッド | がん免疫治療における胃腸の免疫関連有害事象の治療方法 |
| US20200330557A1 (en) * | 2016-08-19 | 2020-10-22 | Brooklyn Immunotherapeutics Llc | Uses of pd-1/pd-l1 inhibitors and/or ctla-4 inhibitors with a biologic containing multiple cytokine components to treat cancer |
| JP2019534308A (ja) * | 2016-11-10 | 2019-11-28 | ネクター セラピューティクス | 免疫療法的腫瘍治療方法 |
| KR102619747B1 (ko) * | 2017-01-10 | 2023-12-29 | 넥타르 테라퓨틱스 | Tlr 효현제 화합물의 다중-아암 중합체 컨쥬게이트 및 관련 면역 요법적 치료 방법 |
| AU2018227810A1 (en) * | 2017-03-01 | 2019-08-29 | Nektar Therapeutics | Immunotherapeutic tumor treatment method using an interleukin-2 receptor alpha, beta-selective agonist in combination with adoptive cell transfer therapy |
| TWI788340B (zh) | 2017-04-07 | 2023-01-01 | 美商必治妥美雅史谷比公司 | 抗icos促效劑抗體及其用途 |
| EP3628010A4 (en) * | 2017-05-02 | 2021-02-17 | Nektar Therapeutics | IMMUNOTHERAPEUTIC TUMOR TREATMENT PROCEDURE |
| RU2745451C1 (ru) | 2017-05-25 | 2021-03-25 | Инститьют Фор Бейсик Сайенс | Антитела к человеческому интерлейкину-2 и их применение |
| US11542312B2 (en) * | 2017-06-19 | 2023-01-03 | Medicenna Therapeutics, Inc. | IL-2 superagonists in combination with anti-PD-1 antibodies |
| US12030940B2 (en) | 2017-08-17 | 2024-07-09 | Nektar Therapeutics | Immunotherapeutic tumor treatment method |
| CN111511762B (zh) | 2017-08-21 | 2025-05-06 | 天演药业公司 | 抗cd137分子及其用途 |
| KR20200084880A (ko) | 2017-11-06 | 2020-07-13 | 브리스톨-마이어스 스큅 컴퍼니 | 종양을 치료하는 방법 |
| US20210154277A1 (en) * | 2017-11-07 | 2021-05-27 | Nektar Therapeutics | Immunotherapeutic combination for treating cancer |
| JP2021502423A (ja) * | 2017-11-13 | 2021-01-28 | バイオエクセル セラピューティクス，インコーポレイテッド | 免疫系の複数のアームを修飾することによってがんを治療するための方法及び組成物 |
| EP3713592A4 (en) | 2017-11-21 | 2022-01-12 | The Board of Trustees of the Leland Stanford Junior University | INTERLEUKIN-2 PARTIAL AGONISTS |
| WO2019148445A1 (en) | 2018-02-02 | 2019-08-08 | Adagene Inc. | Precision/context-dependent activatable antibodies, and methods of making and using the same |
| JP7445597B2 (ja) | 2018-02-15 | 2024-03-07 | センワ バイオサイエンシズ インコーポレイテッド | キノロン類似体及びそれらの塩、組成物、ならびにそれらの使用方法 |
| TW202003565A (zh) | 2018-03-23 | 2020-01-16 | 美商必治妥美雅史谷比公司 | 抗mica及/或micb抗體及其用途 |
| MA52662A (fr) * | 2018-03-28 | 2021-02-17 | Ascendis Pharma Oncology Div A/S | Conjugués d'il-2 |
| IL278615B1 (en) | 2018-05-14 | 2025-10-01 | Werewolf Therapeutics Inc | Activatable interleukin 12 polypeptides and methods of using them |
| ES2955511T3 (es) | 2018-05-14 | 2023-12-04 | Werewolf Therapeutics Inc | Polipéptidos de interleucina 2 activables y métodos de uso de los mismos |
| WO2020095184A1 (en) | 2018-11-05 | 2020-05-14 | Pfizer Inc. | Combinations for treating cancer |
| JP2022509917A (ja) | 2018-11-05 | 2022-01-25 | ファイザー・インク | がんを処置するための組合せ |
| PE20211284A1 (es) | 2018-11-16 | 2021-07-19 | Bristol Myers Squibb Co | Anticuerpos anti-nkg2a y usos de los mismos |
| EP3969035A4 (en) | 2019-05-14 | 2023-06-21 | Werewolf Therapeutics, Inc. | SEPARATION UNITS AND METHODS AND THEIR USE |
| EP4058471A1 (en) | 2019-11-14 | 2022-09-21 | Werewolf Therapeutics, Inc. | Activatable cytokine polypeptides and methods of use thereof |
| KR20220140514A (ko) | 2020-01-10 | 2022-10-18 | 브라이트 피크 테라퓨틱스 아게 | 변형된 il-2 폴리펩타이드 및 그의 용도 |
| CA3166509A1 (en) | 2020-01-14 | 2021-07-22 | Synthekine, Inc. | Biased il2 muteins methods and compositions |
| AU2021280245A1 (en) * | 2020-05-26 | 2022-12-08 | Regeneron Pharmaceuticals, Inc. | Methods of treating cervical cancer by administering a PD-1 inhibitor |
| US12428461B2 (en) | 2020-06-03 | 2025-09-30 | Ascendis Pharma Oncology Division A/S | Treating cancer with a conjugate comprising an IL-2 moiety |
| WO2022098954A1 (en) | 2020-11-06 | 2022-05-12 | Nektar Therapeutics | Tlr agonist compounds and related cancer immunotherapy methods |
| EP4243928A1 (en) | 2020-11-10 | 2023-09-20 | CatalYm GmbH | Anti-gdf15 antibody and a dosage regimen for the treatment of cancer |
| EP4566674A3 (en) | 2020-12-28 | 2025-08-06 | Bristol-Myers Squibb Company | Antibody compositions and methods of use thereof |
| JP2024501029A (ja) | 2020-12-28 | 2024-01-10 | ブリストル－マイヤーズ スクイブ カンパニー | Ｐｄ１／ｐｄ－ｌ１抗体の皮下投与 |
| US20240269293A1 (en) * | 2021-03-29 | 2024-08-15 | Beijing Xuanyi Pharmasciences Co., Ltd. | Protein-macromolecule conjugates and methods of use thereof |
| WO2022212876A1 (en) | 2021-04-02 | 2022-10-06 | The Regents Of The University Of California | Antibodies against cleaved cdcp1 and uses thereof |
| TW202313679A (zh) * | 2021-06-03 | 2023-04-01 | 美商欣爍克斯公司 | 包含il-2接合物及pd-1拮抗劑之頭頸癌組合療法 |
| AU2022306974A1 (en) | 2021-07-09 | 2024-01-04 | Bright Peak Therapeutics Ag | Modified il-2 polypeptides for treatment of inflammatory and autoimmune diseases |
| US20250332252A1 (en) | 2022-06-02 | 2025-10-30 | Bristol-Myers Squibb Company | Antibody compositions and methods of use thereof |
| US20250215087A1 (en) | 2023-12-29 | 2025-07-03 | Bristol-Myers Squibb Company | Combination therapy of kras inhibitor and treg depleting agent |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001000213A1 (en) * | 1999-06-30 | 2001-01-04 | Merck & Co., Inc. | Src kinase inhibitor compounds |
| CN101084012A (zh) * | 2004-05-20 | 2007-12-05 | 津莫吉尼蒂克斯公司 | 使用il－21和单克隆抗体疗法治疗癌症的方法 |
| EP1896582A4 (en) * | 2005-05-09 | 2009-04-08 | Ono Pharmaceutical Co | HUMAN MONOCLONAL ANTIBODIES AGAINST PROGRAMMED CELL DEATH 1 (PD-1) AND METHOD FOR CREATING TREATMENT WITH ANTI-PD-1 ANTIBODIES ALONE OR IN COMBINATION WITH OTHER IMMUNOTHERAPEUTICS |
| JP5081820B2 (ja) | 2005-06-16 | 2012-11-28 | ネクター セラピューティックス | 分解性結合を有する複合体と該複合体の調製に有益なポリマー試薬 |
| MX358399B (es) | 2010-11-12 | 2018-08-16 | Nektar Therapeutics | Conjugados de un resto de interleucina-2 y un polímero. |
| EP2638395A4 (en) | 2010-11-12 | 2016-06-01 | Endocyte Inc | METHOD FOR TREATING CARCINOMA |
| KR20140038382A (ko) * | 2011-03-10 | 2014-03-28 | 프로벡투스 파마슈티컬스 인코포레이티드 | 암의 치료 증대를 위한 국소 면역조절 치료제와 전신 면역조절 치료제의 복합제 |
| PL3134123T3 (pl) * | 2014-02-21 | 2021-07-12 | Nektar Therapeutics (India) Pvt. Ltd. | Agoniści selektywni względem IL-2Rbeta w kombinacji z przeciwciałem anty-CTLA-4 lub z przeciwciałem anty-PD-1 |
-
2015
- 2015-02-20 PL PL15721044T patent/PL3134123T3/pl unknown
- 2015-02-20 RS RS20210363A patent/RS61661B1/sr unknown
- 2015-02-20 US US15/120,214 patent/US10010587B2/en active Active
- 2015-02-20 KR KR1020167023162A patent/KR102410090B1/ko active Active
- 2015-02-20 EP EP20217706.9A patent/EP3834838A1/en not_active Withdrawn
- 2015-02-20 WO PCT/IN2015/000099 patent/WO2015125159A1/en not_active Ceased
- 2015-02-20 AU AU2015220408A patent/AU2015220408B2/en active Active
- 2015-02-20 ES ES15721044T patent/ES2872848T3/es active Active
- 2015-02-20 PT PT157210444T patent/PT3134123T/pt unknown
- 2015-02-20 MX MX2016010870A patent/MX385194B/es unknown
- 2015-02-20 CA CA2937660A patent/CA2937660A1/en active Pending
- 2015-02-20 HR HRP20210377TT patent/HRP20210377T1/hr unknown
- 2015-02-20 EP EP15721044.4A patent/EP3134123B1/en not_active Revoked
- 2015-02-20 IL IL247320A patent/IL247320B/en unknown
- 2015-02-20 CN CN201580009152.0A patent/CN106132438B/zh active Active
- 2015-02-20 SI SI201531552T patent/SI3134123T1/sl unknown
- 2015-02-20 LT LTEP15721044.4T patent/LT3134123T/lt unknown
- 2015-02-20 JP JP2016570201A patent/JP6963385B2/ja active Active
- 2015-02-20 DK DK15721044.4T patent/DK3134123T3/da active
- 2015-02-20 HU HUE15721044A patent/HUE053982T2/hu unknown
- 2015-02-20 SM SM20210191T patent/SMT202100191T1/it unknown
-
2016
- 2016-08-19 MX MX2021009926A patent/MX2021009926A/es unknown
-
2018
- 2018-06-04 US US15/997,487 patent/US10786552B2/en active Active
-
2019
- 2019-02-01 JP JP2019016875A patent/JP2019077723A/ja not_active Withdrawn
-
2020
- 2020-08-04 AU AU2020213296A patent/AU2020213296A1/en not_active Abandoned
- 2020-08-12 US US16/991,936 patent/US20200368321A1/en not_active Abandoned
-
2021
- 2021-02-08 JP JP2021018007A patent/JP2021073296A/ja not_active Withdrawn
- 2021-04-07 CY CY20211100297T patent/CY1124226T1/el unknown
-
2022
- 2022-05-25 AU AU2022203550A patent/AU2022203550A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017506264A5 (cg-RX-API-DMAC7.html) | ||
| Sternberg et al. | A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: final overall survival results and safety update | |
| Antonia et al. | Immuno-oncology combinations: a review of clinical experience and future prospects | |
| PH12019502484A1 (en) | Stable formulations of programmed death receptor 1 (pd-1) antibodies and methods of use thereof | |
| Ghiringhelli et al. | The interplay between the immune system and chemotherapy: emerging methods for optimizing therapy | |
| FI3799885T3 (fi) | Lymfosyyttien estoreittien neutralointi | |
| JP2017536340A5 (cg-RX-API-DMAC7.html) | ||
| MX2018015393A (es) | Anticuerpo lag-3, fragmento de union al antigeno del mismo y aplicacion farmaceutica del mismo. | |
| MA41038B1 (fr) | Composés d'aminopyridyloxypyrazole | |
| RU2017145558A (ru) | Комбинация антагониста pd-1 и олигонуклеотида типа cpg-c для лечения рака | |
| JP2018508483A5 (cg-RX-API-DMAC7.html) | ||
| IL278423B2 (en) | Fidi-1 / Fidi-AL1 inhibitors for cancer treatment | |
| MY200162A (en) | Anti-gitr antibodies and uses thereof | |
| MY196756A (en) | Bispecific molecules having immunoreactivity with pd-1 and ctla-4, and methods of use thereof | |
| JP2015532292A5 (cg-RX-API-DMAC7.html) | ||
| HK1253049A1 (zh) | 糖基相互作用化合物及其使用方法 | |
| JP2016540042A5 (cg-RX-API-DMAC7.html) | ||
| JP2017500057A5 (cg-RX-API-DMAC7.html) | ||
| WO2012177595A9 (en) | Compositions and methods for the therapy and diagnosis of cancer | |
| JP2018516911A5 (cg-RX-API-DMAC7.html) | ||
| HK1250990A1 (zh) | 凝血因子xi抗体及使用方法 | |
| EP4302784A3 (en) | Anti-ntb-a antibodies and related compositions and methods | |
| WO2011106300A3 (en) | Anti-angiogenesis therapy for the treatment of ovarian cancer | |
| WO2015157629A3 (en) | Antibodies, pharmaceutical compositions and uses thereof | |
| CN107801379A (zh) | 抗癌剂 |